Documents for the extraordinary general meeting will be available no later than September 21, 2026.
Further to the notice convening the extraordinary general meeting to be held on October 5, 2026, the Board of Directors’ complete proposals for resolutions will be available at the Company’s offices and on the Company’s website, www.klaria.com, no later than September 21, 2026.
Proxy forms for the extraordinary general meeting will be available at the Company’s offices and on the Company’s website, www.klaria.com, no later than today, September 14, 2026.
The documents will be sent free of charge to shareholders who so request and provide their postal or e-mail address.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Fredrik Hübinette, Chairman of the Board of Directors
info@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.